All stock lists
Unlock the score
Elanco Animal Health Inc (ELAN)
NYSE: ELAN · Real-Time Price · USD
Healthcare · Drug Manufacturers - Specialty & Generic
22.95+0.43 (+1.93%)
Insider Score
/ 100
ELAN Insider Score
Elanco Animal Health Inc has a live Insider Score.
Scored on 5 qualifying trades from 5 insiders in the last 90 days.
Financial Health Score
Sound
From ELAN’s reported statements · Q2 2026 (trailing 12 months)
Profitability8 / 20
Loses money on what it sells.
- Revenue
- $5.02B
- Net income
- -$199.0M
- Net margin
- -4.0%
Leverage0 / 20
Heavily indebted for what it earns.
- Total debt
- $3.92B
- Cash
- $530.0M
- Net debt / EBITDA
- 4.38x
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $3.80B
- Current liabilities
- $1.85B
- Current ratio
- 2.05
Cash generation16 / 20
The business funds itself from operations.
- Operating cash flow
- $617.0M
- Free cash flow
- $379.0M
- FCF margin
- 7.5%
Dilution & runway20 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 499.5M
- Share growth (1y)
- 0.6%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
ELAN Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 1.37 B | 1.37 B | 1.14 B | 1.14 B | 1.24 B |
| Revenue Growth (YoY) | 10.23 % | — | — | — | — |
| Cost of Revenue | 570.00 M | 586.00 M | 555.00 M | 530.00 M | 528.00 M |
| Gross Profit | 798.00 M | 785.00 M | 589.00 M | 607.00 M | 713.00 M |
| SG&A Expense | 449.00 M | 381.00 M | 338.00 M | 351.00 M | 400.00 M |
| R&D Expense | 92.00 M | 97.00 M | 93.00 M | 89.00 M | 92.00 M |
| Operating Expenses | 680.00 M | 616.00 M | 570.00 M | 580.00 M | 628.00 M |
| Operating Income | 118.00 M | 169.00 M | 19.00 M | 27.00 M | 85.00 M |
| Pretax Income | 56.00 M | 87.00 M | -259.00 M | -50.00 M | 25.00 M |
| Tax Provision | 2.00 M | 30.00 M | 17.00 M | -16.00 M | 14.00 M |
| Net Income | 54.00 M | 57.00 M | -276.00 M | -34.00 M | 11.00 M |
| EPS (Basic) | 0.11 | 0.11 | -0.56 | -0.07 | 0.02 |
| EPS (Diluted) | 0.11 | 0.11 | -0.56 | -0.07 | 0.02 |
| Shares Outstanding | 499.50 M | 497.70 M | 496.90 M | 496.80 M | 496.60 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.